No Intrathecal Morphine

Phase 3Small molecule

UUniversity of Toronto

No Intrathecal Morphine is one of 65 small molecule programs targeting Urinary retention. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urinary RetentionActive, not recruiting

Obstructive Sleep ApneaActive, not recruiting

Urinary RetentionPhase 3

Active, not recruiting

Obstructive Sleep ApneaPreclinical

Active, not recruiting

Competition

Competitive Landscape

149 competitors in Obstructive Sleep Apnea

#DrugCompanyPhaseTrials

Asmanex

Novartis

Phase 3

1 2

Mounjaro

Eli Lilly

Phase 3

1 3

Farxiga

AstraZeneca

Phase 3

1 4

Foundayo

Eli Lilly

Phase 3

1 5

MS Contin

Lunesta

3 7

MS Contin

HHikma Pharmaceuticals LLC

Phase 3

2 8

Ketalar

AAultman Health Foundation

Phase 3

2 9

Sunosi

AAxsome Therapeutics, Inc.

Phase 3

1 10

Advil

KKenvue Brands

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Urinary Retention

NCT07050277

Clinical

Trials by Indication[1]

Obstructive Sleep Apnea1 trial

Spinal Morphine for Patients With Obstructive Sleep Apnea

Suspended·UUniversity Health Network, Toronto·N/A·NCT01790971·40 enrolled

Urinary retention1 trial

Post-Operative Urinary Retention on Revision Knee Arthroplasty: the Role of Intrathecal Morphine

Recruiting·UUniversity of Toronto·Phase 3·NCT07050277·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for No Intrathecal Morphine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — No Intrathecal Morphine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for No Intrathecal Morphine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Toronto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Toronto

No Intrathecal Morphine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Obstructive Sleep Apnea1 trial

Urinary retention1 trial

References

Drug Info

Quick Facts

Related News